Amneal Pharmaceuticals Private Limited

Amneal Pharmaceuticals Private Limited, incorporated on April 7, 2006, is a private limited company based in Ahmedabad, Gujarat, India. The company's Corporate Identification Number (CIN) is U24231GJ2006PTC048109. As of January 6, 2026, Amneal Pharmaceuticals Private Limited has an authorized capital of ₹640.00 crore and a paid-up capital of ₹362.77 crore. The registered office is located at 901-911, Iscon Elegance, Opp. Karnavati Club, S.G. Highway, Ahmedabad, Gujarat, 380015.

The company is a subsidiary of Amneal Pharmaceuticals, Inc., a global biopharmaceutical company headquartered in Bridgewater, New Jersey, USA. Amneal Pharmaceuticals, Inc. is publicly traded on the NASDAQ under the ticker symbol AMRX. The company has a diversified portfolio of over 280 generic and specialty pharmaceuticals, primarily within the United States.

Amneal Pharmaceuticals Private Limited operates multiple manufacturing facilities in India, strategically located to serve both domestic and international markets. The company has invested significantly in these facilities, with a total investment of $500 million as of 2023. The most recent facility, established in 2022, focuses on the production of injectable medications. These facilities adhere to current Good Manufacturing Practices (cGMP) and comply with regulatory standards set by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO).

Amneal Pharmaceuticals Private Limited is led by a team of experienced professionals committed to the company's mission of providing high-quality, affordable medicines. The board of directors includes Kanubhai Punambhai Patel, Suresh Punambhai Patel, and Pankil Narendra Kumar Patel. The company's leadership is guided by the principles of honesty and integrity, inspired by the founders' father, Kanu Patel, an industrial pharmacist and pharmaceutical regulatory inspector in India.

Amneal Pharmaceuticals Private Limited has established a significant presence in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for various pharmaceutical products from regulatory bodies such as the FDA, EMA, and the Medicines and Healthcare products Regulatory Agency (MHRA). These approvals enable Amneal to market and distribute its products in these regions, ensuring compliance with stringent quality and safety standards. The company's adherence to Good Manufacturing Practices (GMP) and other regulatory requirements facilitates its market access and competitiveness in these regions.

Amneal Pharmaceuticals Private Limited is actively expanding its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's commitment to quality is demonstrated by its adherence to WHO prequalification standards, which is essential for accessing these markets. By obtaining WHO prequalification, Amneal ensures that its products meet international quality standards, facilitating smoother entry and acceptance in these regions. This strategic approach positions Amneal to address the growing demand for affordable and high-quality medicines in emerging markets.

Amneal Pharmaceuticals Private Limited has adopted a diversified geographic strategy to mitigate concentration risk and enhance its global presence. The company's operations span across North America, Asia, and Europe, with manufacturing facilities in India and Ireland, and distribution and commercial operations in the United States. This strategic diversification allows Amneal to leverage growth opportunities in various regions while balancing potential risks associated with overreliance on a single market. The company's expansion into emerging markets further demonstrates its commitment to global growth and accessibility of its products.

Amneal Pharmaceuticals Private Limited's parent company, Amneal Pharmaceuticals, Inc., has a robust relationship with the U.S. Food and Drug Administration (FDA). The company has multiple FDA facility registrations, reflecting its compliance with U.S. regulatory standards. Amneal has received approvals for Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), indicating its capability to produce generic drugs and active pharmaceutical ingredients for the U.S. market. The company's facilities have undergone FDA inspections, demonstrating adherence to current Good Manufacturing Practices (cGMP). This regulatory compliance underscores Amneal's commitment to delivering safe and effective pharmaceutical products.

Amneal Pharmaceuticals Private Limited's manufacturing facilities comply with Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). This compliance ensures that the company's products meet international quality standards, facilitating market access in regions that require WHO and EU GMP certification. The company's adherence to these standards reflects its commitment to producing high-quality pharmaceutical products for global markets.

Amneal Pharmaceuticals Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses issued by CDSCO, authorizing it to produce pharmaceutical products for both domestic and export markets. Additionally, Amneal has obtained approvals from state drug controllers and export No Objection Certificates (NOCs), enabling it to export its products to various international markets. These regulatory approvals demonstrate Amneal's compliance with Indian pharmaceutical regulations and its commitment to maintaining high manufacturing standards.

As of March 28, 2026, there are no publicly available records indicating that Amneal Pharmaceuticals Private Limited has received FDA Form 483 observations, warning letters, or import alerts. This absence suggests that the company's manufacturing facilities are in good standing with the FDA and other regulatory bodies. Maintaining a clean regulatory record is crucial for ensuring uninterrupted market access and upholding the company's reputation for quality and compliance.

Amneal Pharmaceuticals Private Limited operates in a competitive landscape, with several key players in the pharmaceutical industry. The company's top five exported products—Iron, Spironolactone, Gabapentin, Potassium, and Naproxen—account for a significant portion of its export value. In the Indian market, Amneal faces competition from other pharmaceutical manufacturers offering similar products. The company's adherence to international quality standards, such as WHO prequalification and EU GMP certification, provides a competitive edge in both domestic and international markets. By maintaining high manufacturing standards and a diverse product portfolio, Amneal positions itself as a strong competitor in the pharmaceutical industry.

Amneal Pharmaceuticals Private Limited distinguishes itself through its commitment to quality, regulatory compliance, and a diversified product portfolio. The company's adherence to WHO prequalification and EU GMP standards ensures that its products meet international quality benchmarks, facilitating market access in various regions. Additionally, Amneal's focus on complex dosage forms, including injectables and biosimilars, demonstrates its capability to address a broad range of therapeutic areas. These differentiators enable Amneal to meet the evolving needs of patients and healthcare providers globally.

Amneal Pharmaceuticals Private Limited's strategic direction focuses on expanding its presence in both generic and specialty pharmaceutical markets. The company's investment in complex dosage forms, such as injectables and biosimilars, aligns with the growing demand for specialized treatments. By adhering to international quality standards and obtaining necessary regulatory approvals, Amneal positions itself to capitalize on opportunities in emerging markets. The company's commitment to quality and compliance supports its strategic objectives and future growth prospects.

Amneal Pharmaceuticals Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $106.5 million USD and 2,360 shipments across 28 products in 19 therapeutic categories. The company's top five products—Iron, Spironolactone, Gabapentin, Potassium, and Naproxen—account for 63.6% of its export value, indicating a focused product portfolio. Amneal's adherence to international quality standards, such as WHO prequalification and EU GMP certification, underscores its reliability as a supplier. The company's consistent export performance and commitment to quality make it a dependable partner for pharmaceutical distribution.